{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T07:23:50Z","timestamp":1762327430148,"version":"build-2065373602"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the effects of eculizumab and rituximab on visual function, motor function, and social quality of life in patients with aquaporin-4 antibody positive neuromyelitis optica spectrum disorder (NMOSD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included NMOSD patients treated with eculizumab (EG,\n                      <jats:italic>n<\/jats:italic>\n                      = 114) or rituximab (CG,\n                      <jats:italic>n<\/jats:italic>\n                      = 114) at the Department of Neurology, First Hospital of Hebei Medical University, and the First Hospital of Shanxi Medical University between January 2018 and August 2024. Patients were followed for 6 months to assess changes in visual, motor, and social outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline characteristics, including demographics, disease duration, AQP4-IgG status, annual recurrence rate, EDSS score, and comorbidities, were comparable between groups (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;gt; 0.05). Both groups showed gradual improvement in visual acuity after treatment (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). However, the EG demonstrated significantly better uncorrected visual acuity at 1, 3, and 6 months (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001) and higher corrected visual acuity (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). Visual field defects decreased more in the EG (61.40%\u221233.33%) compared with the CG (64.91%\u221250.88%,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). Abnormal color vision improved in both groups, with greater reduction in the EG, though not statistically significant at 6 months (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.065). Motor function outcomes showed significant time, group, and interaction effects (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). The EG achieved higher Fugl-Meyer Assessment (FMA) scores and lower Modified Ashworth Scale (MAS) scores at all time points (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). Social function (SFS) improved significantly in both groups, with greater gains in the EG (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Anxiety (HAMA) and depression (HAMD) scores decreased in both groups, but reductions were more pronounced in the EG (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NMOSD significantly impairs visual, motor, and social functions. Eculizumab demonstrated superior efficacy over rituximab in improving functional outcomes and quality of life, supporting its role as an effective therapeutic option for NMOSD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1698950","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:26:38Z","timestamp":1762323998000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of eculizumab and rituximab on visual function, motor function and social quality in patients with NMOSD: a comparative study"],"prefix":"10.3389","volume":"16","author":[{"given":"Yihan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoman","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangzeng","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis Optica Spectrum Disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/nyas.12794","article-title":"Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later","volume":"1366","author":"Pittock","year":"2016","journal-title":"Ann N Y Acad Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1212\/NXI.0000000000000468","article-title":"Mortality in neuromyelitis optica is strongly associated with African ancestry","volume":"5","author":"Mealy","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e2265","DOI":"10.1212\/WNL.0000000000006645","article-title":"Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark","volume":"91","author":"Papp","year":"2018","journal-title":"Neurology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jchemneu.2019.01.012","article-title":"Visual impairment in neuromyelitis optica spectrum disorders (NMOSD)","volume":"97","author":"Wu","year":"2019","journal-title":"J Chem Neuroanat."},{"key":"B8","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1007\/s00415-023-11920-x","article-title":"An update on optic neuritis","volume":"270","author":"Kraker","year":"2023","journal-title":"J Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1007\/s00415-021-10783-4","article-title":"Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders","volume":"269","author":"Abboud","year":"2022","journal-title":"J Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"103711","DOI":"10.1016\/j.msard.2022.103711","article-title":"Experiences of social isolation among patients with neuromyelitis optica spectrum disorder in China: a qualitative study","volume":"60","author":"Liao","year":"2022","journal-title":"Mult Scler Relat Disord."},{"key":"B11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/sjopt.sjopt_74_23","article-title":"Eculizumab in myasthenia gravis: a review","volume":"38","author":"Zhou","year":"2024","journal-title":"Saudi J Ophthalmol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jnnp-2021-328665","article-title":"Eculizumab versus rituximab in generalised myasthenia gravis","volume":"93","author":"Nelke","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"B14","volume-title":"Modified Ashworth Scale","author":"Harb","year":"2024"},{"key":"B15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0165-1781(99)00123-7","article-title":"Social functioning scale: new contributions concerning its psychometric characteristics in a Spanish adaptation","volume":"93","author":"Vazquez Morejon","year":"2000","journal-title":"Psychiatry Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s13760-016-0739-6","article-title":"Impact of autonomic dysfunctions on the quality of life in Parkinson's disease patients","volume":"117","author":"Tomic","year":"2017","journal-title":"Acta Neurol Belg."},{"key":"B17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/mds.27268","article-title":"Autonomic dysfunction in Parkinson's disease: a prospective cohort study","volume":"33","author":"Merola","year":"2018","journal-title":"Mov Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.msard.2015.03.007","article-title":"Autonomic symptom burden is associated with MS-related fatigue and quality of life","volume":"4","author":"Cortez","year":"2015","journal-title":"Mult Scler Relat Disord."},{"key":"B19","doi-asserted-by":"publisher","first-page":"757748","DOI":"10.3389\/fneur.2021.757748","article-title":"Autonomic symptoms in older adults are common and associated with health-related quality of life","volume":"12","author":"Renno-Busch","year":"2021","journal-title":"Front Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1177\/1352458517735191","article-title":"Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates","volume":"24","author":"Sepulveda","year":"2018","journal-title":"Mult Scler."},{"key":"B21","doi-asserted-by":"publisher","first-page":"S174","DOI":"10.1016\/j.ophtha.2020.01.027","article-title":"The course of visual recovery after optic neuritis: experience of the optic neuritis treatment trial","volume":"127","author":"Beck","year":"2020","journal-title":"Ophthalmology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nsmb.3196","article-title":"Structural basis for therapeutic inhibition of complement C5","volume":"23","author":"Jore","year":"2016","journal-title":"Nat Struct Mol Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"696387","DOI":"10.3389\/fneur.2021.696387","article-title":"Eculizumab pharmacokinetics and pharmacodynamics in patients with neuromyelitis optica spectrum disorder","volume":"12","author":"Singh","year":"2021","journal-title":"Front Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40265-020-01297-w","article-title":"Eculizumab: a review in neuromyelitis optica spectrum disorder","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs."},{"key":"B25","doi-asserted-by":"publisher","first-page":"17562864231181177","DOI":"10.1177\/17562864231181177","article-title":"Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan","volume":"16","author":"Nakashima","year":"2023","journal-title":"Ther Adv Neurol Disord."},{"key":"B26","first-page":"685","article-title":"The dyschromatopsia of optic neuritis: a descriptive analysis of data from the optic neuritis treatment trial","volume":"93","author":"Katz","year":"1995","journal-title":"Trans Am Ophthalmol Soc."},{"key":"B27","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/archopht.1994.01090190094027","article-title":"Visual field profile of optic neuritis. One-year follow-up in the optic neuritis treatment trial","volume":"112","author":"Keltner","year":"1994","journal-title":"Arch Ophthalmol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1212\/NXI.0000000000000580","article-title":"Neuromyelitis optica spectrum disorder: patient experience and quality of life","volume":"6","author":"Beekman","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1698950\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:26:39Z","timestamp":1762323999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1698950\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":28,"alternative-id":["10.3389\/fneur.2025.1698950"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1698950","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"article-number":"1698950"}}